Skip to main content
Publications
Kovesdy CP, Layton JB , Thapa BB, Curhan GC, Rangel LM, Farjat AE, Liu F, Johannes CB , Vizcaya D, Oberprieler NG. Reduction in Urinary Albumin-to-Creatinine Ratio (UACR) in people with CKD and type 2 diabetes initiating finerenone: a comedication subgroup analysis from the FOUNTAIN platform . Poster presented at the American Society of Nephrology (ASN) Kidney Week 2024; October 24, 2024. San Diego, CA. [abstract] J Am Soc Nephrol. 2024 Oct; 35(Suppl v1):559.
Kovesdy CP, Layton JB , Thapa BB, Curhan GC, Rangel LM, Farjat AE, Liu F, Johannes CB , Vizcaya D, Oberprieler NG. Reduction in Urinary Albumin-to-Creatinine Ratio (UACR) in people with CKD and type 2 diabetes initiating finerenone: a CKD stage subgroup analysis from the FOUNTAIN platform . Poster presented at the American Society of Nephrology (ASN) Kidney Week 2024; October 25, 2024. San Diego, CA. [abstract] J Am Soc Nephrol. 2024 Oct; 35(Suppl v1):559.
Ayoub I, Bensink ME, Zhou X , Wang J , Gong W, Preciado P, Komers R, Inrig JK, Rheault MN, Tachtman H. Patient-reported outcomes in adults with FSGS: sparsentan vs. irbesartan . Poster presented at the American Society of Nephrology (ASN) Kidney Week 2024; October 23, 2024. San Diego, CA. [abstract] J Am Soc Nephrol. 2024 Oct; 35(Suppl v1):281.
Wadhwani S, Bensink M, Peipert JD, Ayoub I, Preciado P, Garbinsky D , Bennett L , Gong W, Inrig J, Komers R. Patient-reported outcomes in the PROTECT clinical trial comparing sparsentan with irbesartan for IgA nephropathy . Poster presented at the American Society of Nephrology (ASN) Kidney Week 2024; October 23, 2024. San Diego, CA. [abstract] J Am Soc Nephrol. 2024 Oct; 35(Suppl v1):723.
Hageman SH, Petitjean C, Pennells L, Kaptoge S, Pajouheshnia R , Tillmann T, Blaha MJ, McClelland RL, Matsushita K, Nambi V, Klungel OH, Souverein PC, van der Schouw YT, Verschuren WM, Lehmann N, Erbel R, Jockel KH, Di Angelantonio E, Visseren FL, Dorresteijn JA. Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2 . Eur J Prev Cardiol. 2023 Oct 26;30(15):1705-14. doi: 10.1093/eurjpc/zwad187
Gilbertson DT, Rothman KJ , Chertow GM, Bradbury BD, Brookhart MA, Liu L, Winkelmayer WC, Sturmer T, Monda KL, Herzog CA, Ashfaq A, Collins AJ, Wetmore JB. Excess deaths attributable to influenza-like illness in the ESRD population . J Am Soc Nephrol. 2019 Feb;30(2):346-53. doi: 10.1681/ASN.2018060581
Chertow GM, Liu J, Monda KL, Gilbertson DT, Brookhart MA, Beaubrun AC, Winkelmayer WC, Pollock A, Herzog CA, Ashfaq A, Sturmer T, Rothman KJ , Bradbury BD, Collins AJ. Epoetin alfa and outcomes in dialysis amid regulatory and payment reform . J Am Soc Nephrol. 2016 Oct;27(10):3129-38. doi: 10.1681/ASN.2015111232
Nussbaumer B, Kaminski-Hartenthaler A, Forneris CA, Winkler D, Sonis JH, Gaynes BN, Wipplinger J, Morgan C, Greenblatt A , Lux LJ, Van Noord MG. Prevention of seasonal affective disorder-systematic review and meta-analyses . Poster presented at the 8th European Public Health Conference; October 14, 2015. Milan, Italy. [abstract] Eur J Public Health. 2015 Oct; 25(suppl_3):ckv172-08. doi: 10.1093/eurpub/ckv172.084
Ferreira-Gonzalez I, Pinar-Sopena J, Ribera A, Marsal JR , Cascant P, Gonzalez-Alujas T, Evangelista A, Brotons C, Moral I, Permanyer-Miralda G, Garcia-Dorado D, Tornos P. Prevalence of calcific aortic valve disease in the elderly and associated risk factors: a population-based study in a Mediterranean area . Eur J Prev Cardiol. 2013 Dec;20(6):1022-30. doi: 10.1177/2047487312451238